Results from the NRG-RTOG 0232 clinical trial adding external beam radiotherapy to brachytherapy in men with intermediate-risk prostate cancer indicate that there was no improvement in freedom from progression rates for patients

Patients with locally advanced rectal cancer with tumors that respond to chemotherapy can safely forego radiation therapy before surgery based on the findings of the phase 3 Alliance PROSPECT trial

Nivolumab added to AVD chemotherapy expected to become new standard for initial treatment for advanced stage disease in adolescents and adults, based on trial data to be presented at 2023 ASCO Annual Meeting plenary session

Results of SWOG S1929 trial show patients with small-cell lung cancer with SLFN11 expression can benefit from PARP inhibitor added to immune checkpoint blockade

Changes in RECIST tumor measures correlate linearly with survival in patients treated with checkpoint inhibitors

Five leading cancer research organizations in the United States are jointly announcing the start of patient enrollment in Molecular Analysis for Combination Therapy Choice (ComboMATCH), a unique, precision medicine initiative to test new combinations of cancer drugs guided by tumor biology

S1714 results at ASCO 2023: Taxane-induced peripheral neuropathy in breast cancer: frequent, clinically significant, and worse with paclitaxel

Extended lymph node removal does not benefit patients with clinically localized muscle-invasive bladder cancer